Predicting human developmental toxicity of pharmaceuticals using human stem-like cells and metabolomics

• US 8,703,424 B2
• Filed: 03/22/2011
• Issued: 04/22/2014
• Est. Priority Date: 03/22/2010
• Status: Active Grant

• Current Assignee: Stemina Biomarker Discovery Incorporated
• Original Assignee: Stemina Biomarker Discovery Incorporated
• Inventors: Smith, Alan M., West, Paul R., Weir-Hauptman, April M., Donley, Elizabeth L. R., Cezar, Gabriela G.
• Primary Examiner(s): Ton, Thaian N
• Application Number:
  US13/069,326
• Publication Number:
  US 20110312019A1
• Time in Patent Office: 1,127 Days
• Field of Search: 435/6.13, 435/325
• US Class Current: 435/6.13
• CPC Class Codes: G01N 33/5014 for testing toxicity
• CPC Class Codes: G01N 33/5073 Stem cells
• CPC Class Codes: G01N 33/6848 Methods of protein analysis involving mass spectrometry

Abstract

The invention provides biomarker profiles of metabolites and methods for screening chemical compounds including pharmaceutical agents, lead and candidate drug compounds and other chemicals using human stem-like cells (hSLCs) or lineage-specific cells produced therefrom. The inventive methods are useful for testing toxicity, particularly developmental toxicity and detecting teratogenic effects of such chemical compounds. Specifically, a more predictive developmental toxicity model, based on an in vitro method that utilizes both hSLCs and metabolomics to discover biomarkers of developmental toxicity is disclosed.

Claims

1. A method of screening the teratogenicity of a test compound, the method comprising the steps of:

(a) culturing human stem cell-like cells (hSLCs);

(i) in the presence of the test compound; and

(ii) in the absence of the test compound;

(b) determining the fold change in arginine associated with hSLCs cultured in the presence of the test compound in comparison with hSLCs cultured in the absence of the test compound;

(c) determining the fold change in asymmetric dimethyl arginine (ADMA) associated with hSLCs cultured in the presence of the test compound in comparison with hSLCs cultured in the absence of the test compound;

(d) determining the ratio of the fold change in arginine to the fold change in ADMA, wherein;

(i) a ratio of less than 0.9 or greater than 1.1 is indicative of the teratogenicity of the test compound; and

(ii) a ratio of greater than 0.9 and less than 1.1 is indicative of the non-teratogenicity of the test compound.

2. The method of claim 1, wherein the hSLCs are further cultured during step a) in the presence of a known non-teratogenic compound.

3. The method of claim 1, wherein the hSLCs comprise human embryonic stem cells (hESCs), human induced pluripotent (iPS) cells, or human embryoid bodies.

4. The method of claim 1, wherein metabolites are identified using a physical separation method.

5. The method of claim 4, wherein the physical separation method is mass spectrometry.

6. The method according to claim 5, wherein the mass spectrometry is liquid chromatography/electro spray ionization mass spectrometry.

7. The method of claim 1, further comprising determining a fold change in one or more of succinic acid, gamma-aminobutyric acid (GABA), isoleucine, aspartic acid, malic acid, glutamic acid and histidine.

8. The method of claim 1, further comprising determining a fold change in five or more of the small molecules listed in Table 8.

9. The method of claim 1, further comprising determining a fold change in ten or more of the small molecules listed in Table 8.

10. The method of claim 1, further comprising determining a fold change in one or more of the small molecules listed in Table 10.

11. The method according to claim 1, wherein the hSLCs comprise human embryonic stem cells (hESCs), human induced pluripotent (iPS) cells, or human embryoid bodies.